CD18 Monoclonal Antibody (2E6), Invitrogen™

Description

• MA1805 targets CD18 in FACS, IA, and IP applications and shows reactivity with mouse samples
• The MA1805 immunogen is cD18
• MA1805 detects CD18 which has a predicted molecular weight of approximately 83 kDa
• This product is a Low Endotoxin formulation
• This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg)
• CD18 integrin beta 2 subunit is a 90 kDa type I transmembrane protein expressed on all leucocytes
• CD18 can combine with integrin molecules CD11a-c to form heterodimers at the cell surface, and these heterodimers are known to participate in the process of cell adhesion as well as cell-surface mediated signaling
• CD18 forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18)
• In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits, and these integrins are essential for proper leukocyte migration, mediating intercellular contacts
• Absence of CD18 leads to leukocyte adhesion deficiency-1, severe reduction of CD18 expression leads to the development of a psoriasiform skin disease
• CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis
• Defects in the CD18 gene are the cause of leukocyte adhesion deficiency type I (LAD1)
• Two transcript variants encoding the CD18 protein have been identified.